|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||33.75 - 38.17|
|52-week range||33.75 - 38.17|
|Beta (5Y monthly)||2.01|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2021 - 11 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The stock market moved higher again on Friday, although the Nasdaq Composite (NASDAQINDEX: ^IXIC) struggled to climb into positive territory. As of just before 3 p.m. EDT, the Nasdaq was up less than 0.1%. Investors have been happy with the returns that the Nasdaq and other major market benchmarks have generated over the past year, but they've been increasingly nervous about whether the stock market is moving into bubble territory.
Shares of gene-editing specialist Editas Medicine (NASDAQ: EDIT) are falling sharply on Friday and were down by 16.7% as of 2:02 p.m. EDT. Goldman Sachs analyst Madhu Kumar initiated coverage of Editas Medicine with a sell rating Friday. Editas Medicine's share price as of the closing of business day yesterday was $40.98.
This April, many previous growth stocks have cooled, and the biotech sector is no exception. FibroGen (NASDAQ: FGEN), Novavax (NASDAQ: NVAX), and Editas Medicine (NASDAQ: EDIT) have all taken a beating for various reasons. It usually is not a reassuring sign to see that, right before going in front of the U.S. Food and Drug Administration (FDA) for review, a company wants to clarify prior data in regards to cardiovascular safety.